CLINICAL_TRIALS
trial_result
· 2018-11-02
Clinical Trial Update: Study of PF-05212384 (Also Known as PKI-587)Administered Intravenously To Subjects With Solid Tumors [Phase 1]
Summary
Phase 1 study of PF-05212384 (PKI-587) given IV in subjects with solid tumors has completed; results posted.
Upgrade for the full analysis, importance score, and drug timeline.
Diseases / indications
Drugs mentioned
Snippet
Sponsor: Pfizer | Conditions: Neoplasms | Phase 1 | Status: COMPLETED | Results posted: 2018-11-02